Alerts will be sent to your verified email
Verify Email
PARMAX
|
Parmax Pharma
|
Emmessar Biotech&Nut
|
Beryl Drugs
|
|
|---|---|---|---|
|
Operational Metrics
|
|||
|
Financials
|
|||
|
5 yr Average ROE
|
-1624.87 % | 13.7 % | 2.54 % |
|
5yr Avg Net Profit Margin
|
-9.48 % | 71.53 % | 0.66 % |
|
Price to Book
|
0.0 | 1.82 | 1.37 |
|
P/E
|
0.0 | 34.15 | 58.69 |
|
5yr Avg Cash Conversion Cycle
|
-161.05 Days | 68.18 Days | -619.24 Days |
|
5yr Average Interest Coverage Ratio
|
1.16 | 815.2 | 1.68 |
|
5yr Avg ROCE
|
-9.94 % | 19.97 % | 5.73 % |
|
5yr Avg Operating Profit Margin
|
3.93 % | -101.39 % | 7.19 % |
|
5 yr average Debt to Equity
|
17.42 | 0.0 | 0.64 |
|
5yr CAGR Net Profit
|
n/a | 0.0 | 72.78 % |
|
5yr Average Return on Assets
|
-6.43 % | 10.86 % | 1.31 % |
|
Shareholdings
|
|||
|
Promoter Holding
|
30.8 % | 59.53 % | 26.38 % |
|
Share Pledged by Promoters
|
0.0 | 0.0 | 0.0 |
|
Change in Promoter Holding (3 Yrs)
|
0.0 | 1.34 % | 1.46 % |
|
Change in Mutual Fund Holding (3 Yrs)
|
0.0 | 0.0 | 0.0 |
|
Parmax Pharma
|
Emmessar Biotech&Nut
|
Beryl Drugs
|
|---|